Mylan Sovaldi Launch


Mylan launches Sovaldi tablets in India

Mylan NV on Monday announced that its subsidiary Mylan Pharmaceuticals Pvt. Ltd. had launched Gilead Sciences’ Sovaldi (sofosbuvir 400mg tablets) in India. This follows Gilead, in February this year, appointing Mylan as its exclusive distributor of Sovaldi in the country. According to a release from Mylan, Sovaldi is indicated for treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. An estimated 12 million people are chronically infected with hepatitis C in India. — N. Ravikumar

Our code of editorial values

This article is closed for comments.
Please Email the Editor

Printable version | Nov 27, 2021 6:09:25 AM |

Next Story